Compare AbbVie Inc (ABBV) vs Lam Research Corporation (LRCX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Lam Research Corporation — how do they compare? AbbVie Inc trades at $253.56 (market cap $449.91B), while Lam Research Corporation trades at $333.24 (market cap $407.85B). The key difference: AbbVie Inc and Lam Research Corporation are close in size by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | LRCX | |
|---|---|---|
Market Cap | $449.91B | $407.85B |
Sector | Health | Technology |
52-Week High | $261.07 | $433.33 |
52-Week Low | $184.85 | $94.84 |
Enterprise Value | $513.38B | $406.83B |
Dividend Yield | 2.72% | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Lam Research (LRCX) trades at $326.13, down 7.19% amid a broader chip stock sell-off, yet maintains a bullish technical signal with strong support at $323. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.47 exceeding expectations, and demonstrates solid fundamentals including a 30.94% net income margin and positive cash flow trends. Analyst sentiment remains overwhelmingly positive with a $378 consensus price target.
LRCX's outlook is supported by AI-driven demand for semiconductor equipment, though valuation multiples appear elevated. Key risks include sector volatility and competitive pressures, but institutional bullishness and consistent execution provide a favorable backdrop for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
